此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

新型超声探头机器人辅助前列腺活检

2026年11月4日 更新者:Johns Hopkins University

机器人辅助前列腺活检与新型超声探头

Prostate cancer (PCa) is the most diagnosed type of cancer and the second leading cause of cancer related deaths among US men, and its incidence has increased steadily in the last decade. Efforts to address the rise in PCa diagnosis without overdetection and overtreatment include targeted biopsy techniques for clinically significant PCa using magnetic resonance imaging (MRI), and precision targeted biopsy guided by ultrasound and fused to the MRI.

The study aims to improve prostate biopsy with a novel ultrasound probe and robot developed at Johns Hopkins, the ProBot device. The trial is a Phase 1 clinical trial to evaluate the safety and feasibility of the new device.

ProBot is an entirely new concept including a novel ultrasound probe and robot kinematics specifically designed for the prostate. It operates with only two degrees of freedom configured such that the motions for 3D image scanning and biopsy may not deform the prostate gland, thus improving the accuracy of MRI-ultrasound fusion and needle targeting at biopsy.

ProBot is a small and lightweight robot (1.3Kg including the ultrasound probe). It allows hands-free operation of its ultrasound probe at 3D image scanning and needle targeting supervised by the urologist.

In addition to MRI-targeted biopsy (TB), at systematic biopsy (SB), instead of using the common template plan that is the same for all patients, the innovative software optimizes the plan for each patient to obtain a diagnosis that is representative of the whole gland histology. The ProBot robot is also uniquely capable of transrectal (TR) and transperineal (TP) biopsy.

The aims of the study are to determine the safety and feasibility of the new device at TR and TP biopsies.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

60

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Sara A Naizghi
  • 电话号码:720-965-9494 4105501980
  • 邮箱:snaizgh1@jh.edu

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21287
        • 招聘中
        • Johns Hopkins Hospital
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Included in the study will be:

  • Men between the ages of 40 and 75

  • Men must have one of the following "high risk" features:

    1. PSA > 4.0 ng/ml and/or abnormal digital rectal examination (DRE)
    2. ASAP (atypical small acinar proliferation) on previous biopsy
  • Men with mpMRI or bpMRI exams, including both PI-RADS ≤2 and PI-RADS ≥3.

Excluded from the study will be patients without available mpMRI exams and patients:

  • Females and children because of the prostate cancer targeted disease.

  • Patients who are not recommended or in whom TR or TP prostate biopsy is considered high-risk:

    1. Patients with previous rectal surgery.
    2. Patients with anal stenosis or coagulopathy.
    3. Patients on active anticoagulation medication (eg. Coumadin, Lovenox, or Heparin).
    4. Patients who cannot tolerate periprostatic Lidocaine block anesthesia or in whom anesthesia is considered high-risk.
  • Patients who already had a prostate biopsy taken with the ProBot investigational device.

  • Vulnerable populations, such as prisoners, institutionalized individuals.

  • Patients who are unwilling or unable to sign informed consent (no assent required).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:设备可行性
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Transrectal biopsy (TR)

Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transrectal path

Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot

实验性的:Transperineal biopsy (TP)

Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transperineal path.

Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Device feasibility as assessed by patient discomfort score
大体时间:Immediately after the procedure

Scale 1-10, 10 highest discomfort

Immediately after the procedure
Device feasibility as assessed by maximal procedural pain
大体时间:Immediately after the procedure

Scale 1-10, 10 highest pain

Immediately after the procedure
Device feasibility as assessed by the rate of complications
大体时间:Throughout the study, each case recorded within 1 month of the procedure

Rate of complications

Throughout the study, each case recorded within 1 month of the procedure
Device feasibility as assessed by serious adverse events
大体时间:Up to 1 month post procedure

Serious Adverse events throughout the study

Up to 1 month post procedure
Device feasibility as assessed by the rate of successful completion of cases
大体时间:Immediately post procedure

Rate of cases completed successfully throughout the study

Immediately post procedure
Device feasibility as assessed by the procedure time
大体时间:Immediately post procedure

Times of the procedures measured in minutes throughout the study

Immediately post procedure

次要结果测量

结果测量
措施说明
大体时间
Prostate cancer detection rates at targeted biopsy (TB)
大体时间:Up to 1 month post procedure

Clinically significant PCa detection rates at TB throughout the study

Up to 1 month post procedure
Prostate cancer detection rates at systematic biopsy (SB)
大体时间:Up to one month post procedure

Clinically significant PCa detection rates at SB throughout the study

Up to one month post procedure
Needle targeting errors
大体时间:Immediately post procedure

Measured in ultrasound throughout the study

Immediately post procedure
Prostate deformations (mm)
大体时间:Immediately post procedure

Maximum deformation of the gland between the start and end of the procedure measured in [mm] throughout the study

Immediately post procedure
Prostate displacement (mm)
大体时间:Immediately post procedure

Displacement of the gland between the start and end of the procedure measured in [mm] throughout the study

Immediately post procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Misop Han, MD、Johns Hopkins University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月23日

初级完成 (估计的)

2030年5月31日

研究完成 (估计的)

2030年5月31日

研究注册日期

首次提交

2025年11月25日

首先提交符合 QC 标准的

2025年11月25日

首次发布 (实际的)

2025年12月8日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅